Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05133037 · ClinicalTrials.gov registry record

AN/BN Risk Factors Study

A clinical trial of Eating Disorders, sponsored by Stanford University.

Active
Registry status
50
Enrollment target
1
Study location

NCT05133037: Active study of Eating Disorders, sponsored by Stanford University.

NCT05133037 is a study of Eating Disorders that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 50 participants, below the 321-participant average among 37 other Eating Disorders trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05133037, a study of Eating Disorders, is active but no longer recruiting, sponsored by Stanford University.

ACTIVE NOT RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

Across the United States, thousands of children and adolescents suffer from eating disorders. Among young women alone, an estimated 2 to 4 percent are dealing with anorexia nervosa. Anorexia nervosa also has the highest mortality rate of any psychiatric disorder and produces a six-fold increased risk for death. Unfortunately, study shows that current treatments are only successful with 25 percent of patients and no eating disorder prevention program has been found to reduce future onset of anorexia nervosa. The goal of this study is to conduct a highly innovative pilot study that will identify risk factors that predict future onset of anorexia nervosa and investigate how the risk processes for anorexia nervosa are different from the risk processes for bulimia nervosa. The proposed pilot study will: * Compare 30 healthy adolescent girls at high risk for anorexia nervosa to 30 healthy adolescent girls at high risk for bulimia nervosa, and 30 healthy adolescent girls at low risk for eating disorder in an effort to document risk processes that are present in early adolescence before anorexia nervosa typically emerges. * Test whether elevations in the hypothesized risk factors predict future onset of anorexia nervosa over a four-year follow-up.

Primary Outcome

Participants will complete the Eating Disorder Diagnostic Interview, administered by a trained interviewer, assessing for Anorexia Nervosa and Bulimia Nervosa.

Conditions Studied

Interventions

  • DEVICE GE MR Scanner

Study Locations (1)

California

  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2021-11-23
Est. Completion 2029-05-26
Stanford University

1,744 total trials

What the registry record for NCT05133037 still lists

NCT05133037 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 321-participant average among 37 other Eating Disorders trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Eating Disorders appearing as the primary indexed condition, and to 1 intervention - of which GE MR Scanner is the first listed.

NCT05133037 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05133037 about?

NCT05133037 is a clinical study titled "AN/BN Risk Factors Study". Across the United States, thousands of children and adolescents suffer from eating disorders. Among young women alone, an estimated 2 to 4 percent are dealing with anorexia nervosa. Anorexia nervosa also has the highest mortality rate of any psychiatric disorder and produces a six-fold increased ris...

What is the current status of trial NCT05133037?

This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2021-11-23. Estimated completion is 2029-05-26.

What conditions does trial NCT05133037 study?

This clinical trial studies the following conditions: Eating Disorders.

What interventions are being tested in trial NCT05133037?

The interventions under investigation include: GE MR Scanner (DEVICE).

Who is sponsoring clinical trial NCT05133037?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05133037 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Eating Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05133037's enrollment target sits among peer trials

50 28th of 37 higher than 10 of 37 other Eating Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Eating Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05133037, the US trial registry maintained by the National Library of Medicine. NCT05133037 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.